Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study-Reference-Cited by-同舟云学术

Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study

Published:2019-07-30 Issue:12 Volume:8 Page:5468-5481
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Sato Nobuaki¹^ORCID,Masuda Norikazu²,Morimoto Takashi³,Ueno Takayuki⁴^ORCID,Kanbayashi Chizuko¹,Kaneko Koji¹,Yasojima Hiroyuki²,Saji Shigehira⁵,Sasano Hironobu⁶,Morita Satoshi⁷,Ohno Shinji⁸,Toi Masakazu⁹

Affiliation:

1. Department of Breast Oncology Niigata Cancer Center Hospital Niigata Japan

2. Department of Surgery, Breast Oncology National Hospital Organization Osaka National Hospital Osaka Japan

3. Department of Breast Surgery Yao Municipal Hospital Osaka Japan

4. Breast Surgical Oncology, Breast Oncology Center Cancer Institute Hospital Tokyo Japan

5. Department of Medical Oncology Fukushima Medical University Fukushima Japan

6. Department of Pathology Tohoku University Miyagi Japan

7. Department of Biomedical Statistics and Bioinformatics Kyoto University Graduate School of Medicine Kyoto Japan

8. Breast Oncology Center Cancer Institute Hospital Tokyo Japan

9. Department of Surgery (Breast Surgery), Graduate School of Medicine Kyoto University Kyoto Japan

Funder

Japan Breast Cancer Research Group